Denmark's Coloplast Q1 revenue growth flat on currency hit; keeps FY forecast

Coloplast A/S

06/02/2026 06:39

Overview

Denmark-based medical device firm's Q1 organic growth was 6%, with EBIT up 3% in constant currencies

Reported revenue in DKK was flat due to a 4%-points negative currency impact

Company to acquire Uromedica, a medical tech firm, expected to close in February 2026

Outlook

Coloplast maintains FY 2025/26 guidance for around 7% organic revenue growth

Company expects high single-digit growth in Interventional Urology

Kerecis growth forecast reduced to around 10% due to Medicare changes

Result Drivers

OSTOMY CARE - Soft start due to negative growth in China and high baseline in the US, expected to improve later in the year

CONTINENCE CARE - Growth driven by strong contribution from Luja for both male and female users

WOUND & TISSUE REPAIR - Kerecis impacted by Medicare reimbursement changes, Advanced Wound Dressings affected by product return in China

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
DKK 7.04 bln
Q1 Net Income
DKK 1.40 bln
Q1 Adjusted EBIT
DKK 1.85 bln
Q1 EBIT
DKK 1.82 bln
Q1 EBIT Margin
26.00%
Q1 Pretax Profit
DKK 1.79 bln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 15 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Coloplast A/S is DKK630.00, about 17.2% above its February 5 closing price of DKK537.40

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release: ID:nGNE7CMqyf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)